long-term epidemiological data absent Metabolic effects potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies Endocrine disruption effects on other hormonal axes with chronic use not well-studied Regulatory & Competitive Sport Status FDA Position Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication: Investigational New Drug status available only for qualified research applications 2024 FDA compounding restrictions both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review Not approved for human use in any formulation or indication Warning letters issued to companies marketing peptides for human therapeutic use Compounding status uncertain as of 2024-2025, regulatory position on compounding pharmacy access remains in flux The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts
A recent study also demonstrated mislocalization of APE1 from the nucleus to the cytoplasm as a possible trigger of oxidative DNA damage in spinal motor neurons expressing mutant SOD1 G93A , despite upregulation of multiple DNA repair enzymes, suggesting that restricted localization of APE1 could inhibit redox homeostasis (Li J
doi: 10.1016/j.ecoenv.2020.110956 35 WangJZhuMWangLChenCSongY
Correlation between Cardiorespiratory Fitness and Platelet Function in Healthy Women
This discrepancy of iron chelation worsening neurodegeneration characterised by local iron overload raises a critical question: why does iron chelation block ferroptosis induced by pro-ferroptotic agents such as RSL3 and erastin (where there is no iron elevation in cell culture), yet fail to protect in the context of human neurodegenerative disease where iron is elevated
